Evidence map›Paper›PMID 33416495›Full record

ArticleeLife2021

Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway.

Dafeng Yang, Stefan Haemmig, Haoyang Zhou, Daniel Pérez-Cremades, Xinghui Sun, Lei Chen, Jie Li, Jorge Haneo-Mejia, Tianlun Yang, Ivana Hollan and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Eyes on fire: a diagnostic and therapeutic dilemma.Internal and emergency medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Review
  10. MicroRNA-181 in cardiovascular disease: Emerging biomarkers and therapeutic targets.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Dafeng Yang *Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Stefan Haemmig *Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Haoyang Zhou *Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Daniel Pérez-CremadesDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Xinghui SunDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Lei ChenDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Jie LiDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Jorge Haneo-MejiaDepartment of Pathology and Laboratory Medicine, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Tianlun YangDepartment of Cardiology, Xiangya Hospital, Central South University, Changsha, China.
Ivana HollanDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Mark W FeinbergDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.ORCID 0000-0001-9523-3859
Brigham and Women's Hospital · USCentral South University · CNChildren's Hospital of Philadelphia · US

Funding

MiR-181b, endothelial cells, and vascular inflammationR01HL115141 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2012 to 2024
$6.8M
miR-615, AKT/eNOS signaling, and angiogenesisR01HL148207 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$2.6M
LncRNA SNHG12, vascular senescence, and atherosclerosisR01HL148355 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$2.5M
KLF10, CD4+ T cells, and transplant arteriopathyR01HL134849 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2017 to 2020
$1.7M
LncRNA MAARS, macrophage apoptosis, and atherosclerosisR01HL153356 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$1.7M
NHLBI NIH HHS R01 HL115141NHLBI NIH HHS R01 HL134849NHLBI NIH HHS R01 HL148207NHLBI NIH HHS R01 HL148355NHLBI NIH HHS R01 HL153356
6 · The paper itself

Abstract

Endothelial cell (EC) activation is an early hallmark in the pathogenesis of chronic vascular diseases. MicroRNA-181b (

Indexed as

AdenosineAnimalsAntirheumatic AgentsArthritis, RheumatoidFemaleHumansInflammationMaleMethotrexateMiceMicroRNAsSignal TransductionAdenosineAntirheumatic AgentsMethotrexateMicroRNAsadenosineendothelial cellshumanimmunologyinflammationmedicinemethotrexatemicroRNAmouse

Identifiers

PMID33416495
PMCPMC7840179
OpenAlexW3120914261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.